Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer

Phase 2

Completed

• Conditions: Prostate Adenocarcinoma; Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer
• Interventions: Drug: Cholecalciferol; Drug: Genistein; Other: Laboratory Biomarker Analysis; Other: Placebo; Other: Pharmacological Study

• Registration Number: NCT01325311
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

This randomized phase II trial studies cholecalciferol and genistein compared to placebo in treating patients with early stage prostate cancer. Cholecalciferol and genistein may slow the growth of cancer cells and may be an effective treatment for prostate cancer.

Detailed Description

PRIMARY OBJECTIVES:

I. To determine differences in prostate tissue steady state concentrations of calcitriol in participants treated with a single dose cholecalciferol (200,000 IU) and G-2535 (which provides 600 mg of genistein) and those receiving placebo.

SECONDARY OBJECTIVES:

I. To determine the effect of each intervention arm and resulting prostate tissue levels of calcitriol on down-stream related biomarkers and related mechanistic pathways in blood and tissue.

OUTLINE: Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive cholecalciferol orally (PO) on day 1 and genistein PO once daily (QD) on days 1-21 or 1-28. Patients then undergo prostatectomy.

ARM II: Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.

Study Timeline

• Study First Submitted: 2011-03-23
• Study First Submitted QC: 2011-03-28
• Study First Posted: 2011-03-29
• Study Start: 2011-12
• Primary Completion: 2014-07
• Study Completion: 2014-07
• Results First Submitted: 2015-12-24
• Status Verified: 2016-06
• Results First Submitted QC: 2016-06-20
• Last Update Submitted: 2016-06-20
• Results First Posted: 2016-08-03
• Last Update Posted: 2016-08-03

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Male
• Target Recruitment: 15

Inclusion Criteria

• Participants must have microscopic confirmation of adenocarcinoma of the prostate within three months of randomization; clinical stage T1 and T2 a, b, or c are allowed
• Participants' prostate cancer must be confined to the prostate (in the clinical judgment of the treating physician)
• Participants must be candidates for prostatectomy
• Participants must have Eastern Cooperative Oncology Group (ECOG) performance status =<1 (Karnofsky >= 70%)
• White blood cell (WBC) within normal limits
• Platelets >= 100 K/uL
• Hemoglobin >= 10 g/dL
• Thyroid-stimulating hormone (TSH) =< 4.20 uIU/mL
• Free T4 =< 12.5 ng/dL
• Bilirubin within upper limit of normal
• Aspartate aminotransferase (AST) =< 1.5 x upper limit of normal
• Creatinine =< 2.0 mg/dL
• Serum calcium: within institutional normal limits
• Participants must agree to stop taking nonsteroidal anti-inflammatory drugs (NSAIDS) during the course of the study, however, low dose aspirin (< 100 mg/day) will be allowed; no wash out period is required
• Participants must be willing to discontinue consuming soy products and ingesting vitamin supplements while participating in this study
• The effects of cholecalciferol and genistein on the developing human fetus at the recommended therapeutic doses are unknown; for this reason, participants must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation
• Participants must have the ability to understand and sign a consent form indicating the investigational nature of the treatment and its potential risks

Read More

Exclusion Criteria

• Participants may not have received any prior therapy for prostate cancer including: chemotherapy, hormonal therapy, brachytherapy, or external radiation
• Participants may not be receiving concurrent systemic therapy for other cancers
• Participants may not be receiving any other investigational agents
• Participants may not be taking the following p450 inducers and inhibitors: carbamazepine, clarithromycin, fluconazole, fosphenytoin, itraconazole, ketoconazole, phenobarbital, phenytoin, rifabutin, rifampin
• Participants who took finasteride or dutasteride within 6 months of the pre-randomization biopsy, are currently taking finasteride or dutasteride, or are planning on taking these agents during study participation
• Participants with a history of allergic reactions attributed to genistein or placebo, or compounds of similar chemical or biologic composition
• Participants with uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
• Participants requires thyroid replacement therapy; Note: participants with a history of thyroid disease > 5 years ago, with current normal thyroid function, will be considered eligible
• Participant has current, known nephrolithiasis or a history of nephrolithiasis within the past 5 years
• Participant has any history of sarcoidosis

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm I (cholecalciferol, genistein)	Laboratory Biomarker Analysis	Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Arm I (cholecalciferol, genistein)	Pharmacological Study	Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Arm II (placebo)	Laboratory Biomarker Analysis	Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Arm II (placebo)	Placebo	Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Arm II (placebo)	Pharmacological Study	Patients receive placebo PO on day 1 and placebo PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Arm I (cholecalciferol, genistein)	Cholecalciferol	Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.
Arm I (cholecalciferol, genistein)	Genistein	Patients receive cholecalciferol PO on day 1 and genistein PO QD on days 1-21 or 1-28. Patients then undergo prostatectomy.

Primary Outcome Measures

Name	Time	Method
Detectability of Calcitriol Levels in Tissue Between the Placebo and Cholecalciferol/Genistein Arms	up to 35 days	To identify the amount of Calcitriol that is found in the tissue comparing Placebo and Cholecalciferol/Genistein
Tissue Levels of Calcitriol Between the Placebo and Cholecalciferol/Genistein Arms	up to Day 35	This is a measure of calcitriol in prostate tissue comparing placebo and cholecalciferol/genistein

Secondary Outcome Measures

Name	Time	Method
Percent of Participants With CYP24 and CYP27B1 SNPs (DNA From Paxgene)	up to Day 35
Levels of Calcitriol in Participants Serum	baseline and Up to Day 35	This is measuring the amount of Calcitriol that was found in the participants blood Serum at baseline and end of study.
Total IGF-2 in Serum at Baseline and Pre-Surgery	Baseline and Up to Day 35	This is measuring the concentration of the Biomarker IGF-2 in blood serum at Baseline and at the end of the study
Total PTH in Serum at Baseline and Pre-Surgery	Baseline and Up to Day 35	This is measuring the concentration of the Biomarker PTH in blood serum at Baseline and at the end of the study
Levels of Calcidiol in the Participants Serum	Baseline and up to day 35	This is measuring the amount of Calcidiol that was found in the participants blood Serum at baseline and end of study
PBMC CYP mRNA Expression of CYP27B1	Up to Day 35	This is a measure of expression of CYP27B1 in comparing placebo to Cholecalciferol/genistein.
Total PSA in Serum	at Baseline and up to Day 35	This is a measure of the concentration of PSA in the blood serum at baseline and at the end of study.
Total IGF-1 in Serum at Baseline and Pre-Surgery	Baseline and up to Day 35	This is measuring the concentration of the Biomarker IGF-1 in blood serum at Baseline and at the end of the study.
PBMC CYP mRNA Expression of CYP24	Baseline and Up to Day 35	This is a measure of expression of CYP24 in comparing placebo to Cholecalciferol/genistein.
Serum Calcium Levels at Baseline and Pre-Surgery	Baseline and Day 35	This is a measurement of calcium in the Blood serum at baseline and at the end of the study.
Total IGFBP-3 in Serum at Baseline and Pre-Surgery	Baseline and Up to Day 35	This is measuring the concentration of the Biomarker IGFBP-3 in blood serum at Baseline and at the end of the study.
Immunohistochemistry Measurements in Benign Prostate Tissue (BPT)	Up to Day 35	The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm); This is to serve as normalized control data to determine expression of protein.; The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).; This Optical Density is based on fluorescence.
Immunohistochemistry Measurements in Prostate Cancer Tissue (PCA)	Up to day Day 35	The Immunohistochemistry measurement for: AR (Nucleus), VDR (Cytoplasm), p21 (Nucleus), PGE2 (Cytoplasm), TUNEL Pos (Nucleus), Caspase 3 (Cytoplasm), PSMA (Cytoplasm), IGF-1 and IGF-2 (Cytoplasm), Akt (Nucleus and Cytoplasm), and pAkt (nucleus and Cytoplasm); This is to serve as normalized case data to determine expression of protein.; The normalized optical densities were measured as optical density per unit area by densitometric scanning using Vectra imaging system (Perkin Elmer).; This Optical Density is based on fluorescence.

Trial Locations

Locations (11)

Carolina Urologic Research Center; 🇺🇸 Myrtle Beach, South Carolina, United States

University of Alabama at Birmingham Cancer Center; 🇺🇸 Birmingham, Alabama, United States

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital; 🇺🇸 Baltimore, Maryland, United States

Johns Hopkins University/Sidney Kimmel Cancer Center; 🇺🇸 Baltimore, Maryland, United States

Lahey Hospital and Medical Center; 🇺🇸 Burlington, Massachusetts, United States

Minneapolis Veterans Medical Center; 🇺🇸 Minneapolis, Minnesota, United States

University of Minnesota Medical Center-Fairview; 🇺🇸 Minneapolis, Minnesota, United States

University of Rochester; 🇺🇸 Rochester, New York, United States

University of Oklahoma Health Sciences Center; 🇺🇸 Oklahoma City, Oklahoma, United States

Urology San Antonio Research PA; 🇺🇸 San Antonio, Texas, United States

University of Wisconsin Hospital and Clinics; 🇺🇸 Madison, Wisconsin, United States